ClinicalTrials.gg
RecruitingNCT06837311PSDMUpdated Jul 21, 2025

Post-Stroke Secondary Prevention With Digital Monitoring

An interventional study of Ecological Momentary Assessment (EMA) and Biological assessment in Stroke, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-21.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Stroke by University Hospital, Bordeaux — 9 open to participants now, 10 under way, 2 of them phase 3. Stroke · University Hospital, Bordeaux.

Planned enrollment
3rd of 22
388 · median 166
Started
2025
with 2 others
No phase
17 of 27
6 open now
Registered
24th of 27
by date

Among the 27 studies in Stroke by University Hospital, Bordeaux, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 17 with no phase, and was the 24th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 27 studies in Stroke by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Stroke by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

Stroke is the second leading cause of death and a major cause of disability worldwide. In 2019, Disability-Adjusted Life-Years (DALYs) related to stroke was estimated to have reached 143 million. Modifiable stroke risk-factors, which include poor lifestyle habits (tobacco, alcohol and illicit drug abuse, dietary patterns at risk, low physical activity), account for 90 % of the risk of stroke. Stroke complications and the risk of stroke recurrence is highly dependent on the control of these risk factors. Thus, the secondary prevention of stroke requires profound lifestyle modifications including substance use cessation and diet changes. National guidelines for stroke clinical practice advocate an immediate cessation of consumption of all substances but without recommendations on specific therapeutic regimens. Moreover, none address the management of poor coping with stress or mood problems though they are major population attributable risk factors of stroke and constitute major barriers of behavior changes achievement. Yet, post-stroke emotional impairments are frequent, post-stroke depression and anxiety being the most frequent (prevalence is 30% and 25%, respectively). Importantly, independently from stroke, emotional impairments or disorders and Substance Related and Addiction Disorders (SRADs) are frequent comorbid conditions (dual disorders) with debilitating consequences and the interplay between the two conditions makes rehabilitation more complex. This suggests that taking into account stroke patients' mental health status might improve not only the management of post-stroke emotional impairments but also the control of stroke vascular risk factors.

Regarding secondary prevention programs focusing on behavioral changes among Cardiovascular and Cerebrovascular Disease (CVD) patients, the literature is sparse and studies on smoking cessation are the most widely documented. Despite the risk of smoking after a myocardial infarct or a stroke/Transient Ischemic Attack (TIA), less than half of patients quit smoking after the event or achieve long-term abstinence.

To increase treatment adherence and efficacy, besides systematically screening lifestyle habits and evaluating the patients' mental health and motivation to change in clinical routine, experts in the domain emphasize the need to:

  • start delivering treatment as early as possible, ideally during hospitalization;
  • tailor the intensity of the treatment (combination of pharmacological medications +/- behavioral intervention; frequency of the follow-up/contacts) according to the risk profile of each patient, particularly depending on the level of dependence and the presence of comorbid emotional difficulties/psychiatric disorders.

After hospital discharge, in standard care, the follow-up visit is scheduled 4 to 6 months post-stroke. Knowing that the vast majority of smoking relapses occur in the weeks following stroke, it appears that this period is of high risk for missing the goal of stroke secondary prevention. Therefore, new approaches are urgently needed that would allow for the day-to-day examination of clinical change in the immediate days and weeks following discharge from the stroke acute-care unit to optimize the patient's recovery and quality of life.

The potential pivotal role of eHealth development has been advocated by the World Health Organization, which considers e-Health as a cost-effective and secure use of information and communication technologies (ICT). Used in the context of stroke secondary prevention, eHealth technologies should give each patient the opportunity to describe his/her own experiences and symptoms and the contexts of daily life in which they occur that may constitute negative factors for post-stroke recovery. Post-stroke management would thus be optimized through a person-centered, intense and multidisciplinary care program.

Investigators believe apTeleCare would allow for such a day-to-day examination of clinical change in the immediate days and weeks following discharge from the stroke acute-care unit. It offers the possibility not only to closely monitor patients' experiences and symptoms and the contexts of daily life in which they occur, but also to inform the clinical team in real-time via specific alerts that depend on the type and level of difficulties the patients encounter for adopting the expected changes in their lifestyle

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • At least 18 years of age and younger than 80 years;
  • Recent (≤ 15 days) clinically symptomatic ischemic or hemorrhagic stroke documented through brain imaging (CT or MRI) or a with an Predictive Risk Score (ABCD2) ≥ 4;
  • Returning to the neurovascular unit for the standard care post-stroke follow-up visits;
  • National Institute Health Stroke Scale (NIHSS) \< 15;
  • modified Rankin scale ≤ 4;
  • No severe cognitive impairment as defined by the neurologist;
  • Current smokers (smoking at least 1 cigarette per day during the month before admission)
  • Able to use a smartphone
  • Living in an area with internet coverage
  • Written by the patient;
  • Coverage by the French National Health Insurance

Exclusion criteria

Exclusion Criteria:

  • Subarachnoid hemorrhage; Dementia syndrome or other central neurologic disorder;
  • Severe aphasia (NIHSS item 9 ≥ 2)
  • Severe visual impairment interfering with the completion of evaluations;
  • Severely impaired physical and/or mental health that, according to the neurologist, may affect the participant's capacity to participate in the study;
  • Individuals already undergoing treatment for tobacco cessation and/or SRADs at admission in the stroke unit;
  • Pregnancy or breastfeeding;
  • Inability to read French;
  • Individuals under legal protection or unable to express personally their consent
  • Participation in another protocol modifying the patient's follow-up status.
  • Person deprived of liberty
  • Person in emergency situation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
388 participants (estimated)

Study arms

  • Experimental
    Intervention

    Device: Ecological Momentary Assessment (EMA) · Biological: Biological assessment · Behavioral: Psychological examination and Substance Use symptomatology · Other: Treatment as usual (TAU) · Diagnostic Test: Expired carbon monoxide (CO)

  • Other
    Treatment as usual

    Biological: Biological assessment · Behavioral: Psychological examination and Substance Use symptomatology · Other: Treatment as usual (TAU) · Diagnostic Test: Expired carbon monoxide (CO)

Interventions

  • DeviceEcological Momentary Assessment (EMA)

    Daily ecological momentary assessment (EMA), in addition to treatment as usual (TAU) using apTeleCare eHealth device. Daily surveys includes questions reflecting all Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 symptom criteria for Depression, Generalized Anxiety Disorder, Post-Traumatic Symptom Disorder, evaluations of substance use (including dietary items at risk) as well as of two symptoms predictive of relapse (craving and loss of control), medication compliance and physical activity

  • BiologicalBiological assessment

    Routine Biological assessment and of substance use

  • BehavioralPsychological examination and Substance Use symptomatology

    Substance use symptomatology ; Neuropsychiatric symptomatology ; Functional outcomes ; Neurologic and Cardiovascular outcomes

  • OtherTreatment as usual (TAU)

    Treatment as usual (TAU)

  • Diagnostic testExpired carbon monoxide (CO)

    Expired carbon monoxide (CO) measurement

06

What researchers measure

Primary outcomes

  1. Expired carbon monoxide (CO) rate

    Prevalence tobacco abstinence (Expired CO ≤ 8 ppm) 6 months after acute ward discharge.

    Time frame: 6 months

Secondary outcomes

  1. Level of risk and prevalence of Substance-related and addictive disorders (SRADs)

    Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). It consists of 8 questions covering tobacco, alcohol, cannabis, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opiates, and 'other drugs. Twenty-eight domains/scores are derived from these questions

    Time frame: Day 0

  2. Level of risk and prevalence of Substance-related and addictive disorders (SRADs)

    Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). It consists of 8 questions covering tobacco, alcohol, cannabis, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opiates, and 'other drugs. Twenty-eight domains/scores are derived from these questions

    Time frame: 3 Months

  3. Level of risk and prevalence of Substance-related and addictive disorders (SRADs)

    Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). It consists of 8 questions covering tobacco, alcohol, cannabis, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opiates, and 'other drugs. Twenty-eight domains/scores are derived from these questions

    Time frame: 6 Months

  4. Level of risk and prevalence of Substance-related and addictive disorders (SRADs)

    Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). It consists of 8 questions covering tobacco, alcohol, cannabis, amphetamine-type stimulants, inhalants, sedatives, hallucinogens, opiates, and 'other drugs. Twenty-eight domains/scores are derived from these questions

    Time frame: 12 Months

  5. Fagerström Test for Nicotine Dependence (FTND) score

    Nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) which includes 10 items. Scores can range from 0 to 10. The recommended cut-off scores to index the categories of nicotine dependence severity are as follows: below 2 = no dependence, 3 to 4 = mild severity, 5 to 6 = moderate severity, 7 to 10 = extreme severity.

    Time frame: Day 0

  6. Fagerström Test for Nicotine Dependence (FTND) score

    Nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) which includes 10 items. Scores can range from 0 to 10. The recommended cut-off scores to index the categories of nicotine dependence severity are as follows: below 2 = no dependence, 3 to 4 = mild severity, 5 to 6 = moderate severity, 7 to 10 = extreme severity.

    Time frame: 3 months

  7. Fagerström Test for Nicotine Dependence (FTND) score

    Nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) which includes 10 items. Scores can range from 0 to 10. The recommended cut-off scores to index the categories of nicotine dependence severity are as follows: below 2 = no dependence, 3 to 4 = mild severity, 5 to 6 = moderate severity, 7 to 10 = extreme severity.

    Time frame: 6 months

  8. Fagerström Test for Nicotine Dependence (FTND) score

    Nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) which includes 10 items. Scores can range from 0 to 10. The recommended cut-off scores to index the categories of nicotine dependence severity are as follows: below 2 = no dependence, 3 to 4 = mild severity, 5 to 6 = moderate severity, 7 to 10 = extreme severity.

    Time frame: 12 months

  9. modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) score

    Includes one question to assess each of the 11 DSM 5 diagnostic criteria for SRADs transposed to food items as well as two questions to assess clinically significant distress and impairment. Food Addiction is mild if there are 2 or 3 symptoms and clinically significant impairment/distress, moderate if there are 4 or 5 symptoms and significant impairment/distress, and severe if there are 6 or more symptoms and significant impairment/distress.

    Time frame: Day 0

  10. modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) score

    Includes one question to assess each of the 11 DSM 5 diagnostic criteria for SRADs transposed to food items as well as two questions to assess clinically significant distress and impairment. Food Addiction is mild if there are 2 or 3 symptoms and clinically significant impairment/distress, moderate if there are 4 or 5 symptoms and significant impairment/distress, and severe if there are 6 or more symptoms and significant impairment/distress.

    Time frame: 3 Months

  11. modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) score

    Includes one question to assess each of the 11 DSM 5 diagnostic criteria for SRADs transposed to food items as well as two questions to assess clinically significant distress and impairment. Food Addiction is mild if there are 2 or 3 symptoms and clinically significant impairment/distress, moderate if there are 4 or 5 symptoms and significant impairment/distress, and severe if there are 6 or more symptoms and significant impairment/distress.

    Time frame: 6 Months

  12. modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) score

    Includes one question to assess each of the 11 DSM 5 diagnostic criteria for SRADs transposed to food items as well as two questions to assess clinically significant distress and impairment. Food Addiction is mild if there are 2 or 3 symptoms and clinically significant impairment/distress, moderate if there are 4 or 5 symptoms and significant impairment/distress, and severe if there are 6 or more symptoms and significant impairment/distress.

    Time frame: 12 Months

  13. Alcohol Use Disorder Identification Test (AUDIT) Score

    Alcohol dependence test. 10 items. Scores can range from 0 to 40. The recommended cut-off scores to index the categories of alcohol dependence severity are as follows: from 6 to 12 for women and 7 to 12 for men = moderate severity, and above 12 = extreme severity for both sexes.

    Time frame: Day 0

  14. Alcohol Use Disorder Identification Test (AUDIT) Score

    Alcohol dependence test. 10 items. Scores can range from 0 to 40. The recommended cut-off scores to index the categories of alcohol dependence severity are as follows: from 6 to 12 for women and 7 to 12 for men = moderate severity, and above 12 = extreme severity for both sexes.

    Time frame: 3 months

  15. Alcohol Use Disorder Identification Test (AUDIT) Score

    Alcohol dependence test. 10 items. Scores can range from 0 to 40. The recommended cut-off scores to index the categories of alcohol dependence severity are as follows: from 6 to 12 for women and 7 to 12 for men = moderate severity, and above 12 = extreme severity for both sexes.

    Time frame: 6 months

  16. Alcohol Use Disorder Identification Test (AUDIT) Score

    Alcohol dependence test. 10 items. Scores can range from 0 to 40. The recommended cut-off scores to index the categories of alcohol dependence severity are as follows: from 6 to 12 for women and 7 to 12 for men = moderate severity, and above 12 = extreme severity for both sexes.

    Time frame: 12 months

  17. Cannabis Abuse Screening Test (CAST) score

    6 items. Scores can range from 0 to 6. The recommended cut-off scores to index the categories of cannabis dependence severity are as follows: below 2 = low risk of dependence, a score of 2 = moderate risk of dependence, and 3 or more = high risk of dependence.

    Time frame: Day 0

  18. Cannabis Abuse Screening Test (CAST) score

    6 items. Scores can range from 0 to 6. The recommended cut-off scores to index the categories of cannabis dependence severity are as follows: below 2 = low risk of dependence, a score of 2 = moderate risk of dependence, and 3 or more = high risk of dependence.

    Time frame: 3 Months

  19. Cannabis Abuse Screening Test (CAST) score

    6 items. Scores can range from 0 to 6. The recommended cut-off scores to index the categories of cannabis dependence severity are as follows: below 2 = low risk of dependence, a score of 2 = moderate risk of dependence, and 3 or more = high risk of dependence.

    Time frame: 6 Months

  20. Cannabis Abuse Screening Test (CAST) score

    6 items. Scores can range from 0 to 6. The recommended cut-off scores to index the categories of cannabis dependence severity are as follows: below 2 = low risk of dependence, a score of 2 = moderate risk of dependence, and 3 or more = high risk of dependence.

    Time frame: 12 Months

  21. Readiness Ruler or Substance Use Motivation Ruler score

    Asks the respondent to rank his/her motivation to end his/her substance use on a Visual Analog Scale from 1 (Absolutely no motivation to quit) to 10 (No doubt about the decision to be sober) and to list some motivations. The participant will be instructed to provide at least one motivation or more if relevant.

    Time frame: Day 0

  22. Readiness Ruler or Substance Use Motivation Ruler score

    Asks the respondent to rank his/her motivation to end his/her substance use on a Visual Analog Scale from 1 (Absolutely no motivation to quit) to 10 (No doubt about the decision to be sober) and to list some motivations. The participant will be instructed to provide at least one motivation or more if relevant.

    Time frame: 3 months

  23. Readiness Ruler or Substance Use Motivation Ruler score

    Asks the respondent to rank his/her motivation to end his/her substance use on a Visual Analog Scale from 1 (Absolutely no motivation to quit) to 10 (No doubt about the decision to be sober) and to list some motivations. The participant will be instructed to provide at least one motivation or more if relevant.

    Time frame: 6 months

  24. Readiness Ruler or Substance Use Motivation Ruler score

    Asks the respondent to rank his/her motivation to end his/her substance use on a Visual Analog Scale from 1 (Absolutely no motivation to quit) to 10 (No doubt about the decision to be sober) and to list some motivations. The participant will be instructed to provide at least one motivation or more if relevant.

    Time frame: 12 months

  25. Hospital Anxiety and Depression scale (HAD) score

    assesses the perceived level of depressive (7 items) and anxiety (7 items). For each subscale, a score of 7 or more is considered indexing depression and anxiety caseness.

    Time frame: Day 0

  26. Hospital Anxiety and Depression scale (HAD) score

    assesses the perceived level of depressive (7 items) and anxiety (7 items). For each subscale, a score of 7 or more is considered indexing depression and anxiety caseness.

    Time frame: 3 Months

  27. Hospital Anxiety and Depression scale (HAD) score

    assesses the perceived level of depressive (7 items) and anxiety (7 items). For each subscale, a score of 7 or more is considered indexing depression and anxiety caseness.

    Time frame: 6 Months

  28. Hospital Anxiety and Depression scale (HAD) score

    assesses the perceived level of depressive (7 items) and anxiety (7 items). For each subscale, a score of 7 or more is considered indexing depression and anxiety caseness.

    Time frame: 12 Months

  29. Multidimensional Assessment of Thymic States scale (MAThYS) Score

    visual analog scale of 20 items relating to individual states as perceived by the patient for the preceding week. Items can be grouped into five quantitative dimensions ranging each from inhibition to excitation: 1. emotional reactivity, 2. thought processes, 3. psychomotor function, 4. Motivation, and 5. sensory perception

    Time frame: Day 0

  30. Multidimensional Assessment of Thymic States scale (MAThYS) Score

    visual analog scale of 20 items relating to individual states as perceived by the patient for the preceding week. Items can be grouped into five quantitative dimensions ranging each from inhibition to excitation: 1. emotional reactivity, 2. thought processes, 3. psychomotor function, 4. Motivation, and 5. sensory perception

    Time frame: 3 Months

  31. Multidimensional Assessment of Thymic States scale (MAThYS) Score

    visual analog scale of 20 items relating to individual states as perceived by the patient for the preceding week. Items can be grouped into five quantitative dimensions ranging each from inhibition to excitation: 1. emotional reactivity, 2. thought processes, 3. psychomotor function, 4. Motivation, and 5. sensory perception

    Time frame: 6 Months

  32. Multidimensional Assessment of Thymic States scale (MAThYS) Score

    visual analog scale of 20 items relating to individual states as perceived by the patient for the preceding week. Items can be grouped into five quantitative dimensions ranging each from inhibition to excitation: 1. emotional reactivity, 2. thought processes, 3. psychomotor function, 4. Motivation, and 5. sensory perception

    Time frame: 12 Months

  33. Checklist for Cognitive and Emotional Consequences following stroke (CLCE-24) score

    standardized instrument that includes 13 cognitive items, 9 emotional items, and 2 additional open-ended, non-specified items concerning potential additional difficulties not evaluated by the other items. The scoring of each item ranges from 0 (not present) to 3 (present and affecting daily life).

    Time frame: Day 0

  34. Checklist for Cognitive and Emotional Consequences following stroke (CLCE-24) score

    standardized instrument that includes 13 cognitive items, 9 emotional items, and 2 additional open-ended, non-specified items concerning potential additional difficulties not evaluated by the other items. The scoring of each item ranges from 0 (not present) to 3 (present and affecting daily life).

    Time frame: 3 Months

  35. Checklist for Cognitive and Emotional Consequences following stroke (CLCE-24) score

    standardized instrument that includes 13 cognitive items, 9 emotional items, and 2 additional open-ended, non-specified items concerning potential additional difficulties not evaluated by the other items. The scoring of each item ranges from 0 (not present) to 3 (present and affecting daily life).

    Time frame: 6 Months

  36. Checklist for Cognitive and Emotional Consequences following stroke (CLCE-24) score

    standardized instrument that includes 13 cognitive items, 9 emotional items, and 2 additional open-ended, non-specified items concerning potential additional difficulties not evaluated by the other items. The scoring of each item ranges from 0 (not present) to 3 (present and affecting daily life).

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 24 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 20, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Mar 25, 2027
CompletionEst.
Mar 25, 2028
Last update
Jul 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06837311
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Mar 25, 2025
Primary completion
Mar 25, 2027 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Jul 21, 2025

Study contacts

Igor SIBON
Contact
igor.sibon@chu-bordeaux.fr
0556795520
Igor SIBON
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion